# A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.

> **NCT01237236** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 156 (actual)

## Conditions studied

- Advanced Solid Tumor
- Lymphomas

## Interventions

- **DRUG:** LEE011

## Key facts

- **NCT ID:** NCT01237236
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-21
- **Primary completion:** 2017-03-09
- **Final completion:** 2017-03-09
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01237236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01237236, "A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01237236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*